BCL2 and B-cell chronic lymphocytic leukemia: The therapeutic strategy of targeting anti-apoptotic BCL-2 proteins has been clinically validated by the FDA approval of venetoclax for the treatment of various hematologic malignancies including CLL and SLL as a single agent, and for AML in combination with low-intensity chemotherapy [22].